{"protocolSection":{"identificationModule":{"nctId":"NCT00474630","orgStudyIdInfo":{"id":"NB-304"},"secondaryIdInfos":[{"id":"COR-Diabetes","type":"OTHER","domain":"Orexigen Therapeutics, Inc."}],"organization":{"fullName":"Orexigen Therapeutics, Inc","class":"INDUSTRY"},"briefTitle":"A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes","officialTitle":"A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Naltrexone 32 mg Sustained Release (SR)/Bupropion 360 mg Sustained Release (SR) and Placebo in Obese Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"statusVerifiedDate":"2014-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2007-05"},"primaryCompletionDateStruct":{"date":"2009-06","type":"ACTUAL"},"completionDateStruct":{"date":"2009-06","type":"ACTUAL"},"studyFirstSubmitDate":"2007-05-15","studyFirstSubmitQcDate":"2007-05-15","studyFirstPostDateStruct":{"date":"2007-05-17","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-10-10","resultsFirstSubmitQcDate":"2014-11-18","resultsFirstPostDateStruct":{"date":"2014-11-21","type":"ESTIMATED"},"dispFirstSubmitDate":"2012-10-25","dispFirstSubmitQcDate":"2012-10-25","dispFirstPostDateStruct":{"date":"2012-10-31","type":"ESTIMATED"},"lastUpdateSubmitDate":"2014-11-18","lastUpdatePostDateStruct":{"date":"2014-11-21","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Orexigen Therapeutics, Inc","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this study is determine whether the combination of naltrexone SR and bupropion SR is safe and effective in treating obesity in subjects with type 2 diabetes.","detailedDescription":"Optimal care of patients with diabetes mellitus includes vigorous and persistent efforts to achieve physiologic control of blood glucose as well as other often associated conditions including hypertension, dyslipidemia and excess weight. Pharmacologic interventions for the treatment of obesity in type 2 diabetes have shown significant reductions in HbA1c. Two Phase II clinical trials demonstrated that a combination of bupropion SR and naltrexone is associated with greater weight loss than bupropion SR alone, naltrexone alone, or placebo in subjects with uncomplicated obesity. The current study investigated the safety and efficacy of the combination of naltrexone SR and bupropion SR compared to placebo in obese subjects with type 2 diabetes mellitus."},"conditionsModule":{"conditions":["Obesity","Overweight","Diabetes Mellitus, Type 2"],"keywords":["Obesity","Overweight","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":505,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"NB32","type":"EXPERIMENTAL","description":"Naltrexone SR 32 mg/bupropion SR 360 mg/ day with ancillary therapy","interventionNames":["Drug: Naltrexone SR 32 mg/bupropion SR 360 mg/ day","Behavioral: Ancillary therapy"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Placebo with ancillary therapy","interventionNames":["Drug: Placebo","Behavioral: Ancillary therapy"]}],"interventions":[{"type":"DRUG","name":"Naltrexone SR 32 mg/bupropion SR 360 mg/ day","armGroupLabels":["NB32"],"otherNames":["NB32"]},{"type":"DRUG","name":"Placebo","armGroupLabels":["Placebo"]},{"type":"BEHAVIORAL","name":"Ancillary therapy","description":"Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling","armGroupLabels":["NB32","Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Co-primary: Body Weight- Mean Percent Change","timeFrame":"Baseline, 56 weeks"},{"measure":"Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease","timeFrame":"Baseline, 56 weeks"}],"secondaryOutcomes":[{"measure":"Change in HbA1c Levels","timeFrame":"Baseline, 56 weeks"},{"measure":"Change in Fasting Triglycerides Levels, Using Log-transformed Data","timeFrame":"Baseline, 56 weeks"},{"measure":"Change in Fasting HDL Cholesterol Levels","timeFrame":"Baseline, 56 weeks"},{"measure":"Change in Fasting Blood Glucose Levels","timeFrame":"Baseline, 56 weeks"},{"measure":"Change in Waist Circumference","timeFrame":"Baseline, 56 weeks"},{"measure":"Body Weight- Proportion of Subjects With ≥10% Decrease","timeFrame":"Baseline, 56 weeks"},{"measure":"HbA1c- Proportion of Subjects With HbA1c <7% at Endpoint","timeFrame":"Baseline, 56 weeks"},{"measure":"Percent of Subjects Requiring Rescue Medications for Diabetes","timeFrame":"Baseline, 56 weeks"},{"measure":"Percent of Subjects With Dose Reduction in Oral Antidiabetes Medications","timeFrame":"Baseline, 56 weeks"},{"measure":"Percent of Subjects With Dose Increase in Oral Antidiabetes Medications","timeFrame":"Baseline, 56 weeks"},{"measure":"Change in HOMA-IR Levels, Using Log-transformed Data","description":"HOMA-IR= Homeostasis Model Assessment-Insulin Resistance","timeFrame":"Baseline, 56 weeks"},{"measure":"Change in Fasting Insulin Levels, Using Log-transformed Data","timeFrame":"Baseline, 56 weeks"},{"measure":"HbA1c- Proportion of Subjects With HbA1c <6.5% at Endpoint","timeFrame":"Baseline, 56 weeks"},{"measure":"Change in IWQOL-Lite Total Scores","description":"IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment","timeFrame":"Baseline, 56 weeks"},{"measure":"Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data","timeFrame":"Baseline, 56 weeks"},{"measure":"Percent of Subjects Discontinuing Due to Poor Glycemic Control","description":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed. Odds ratio not calculated as there were no subjects in the NB32 group that discontinued due to poor glycemic control.","timeFrame":"Baseline, 56 weeks"},{"measure":"Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire","description":"Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult","timeFrame":"Baseline, 56 weeks"},{"measure":"Change in Fasting LDL Cholesterol Levels","timeFrame":"Baseline, 56 weeks"},{"measure":"Change in Systolic Blood Pressure","timeFrame":"Baseline, 56 weeks"},{"measure":"Change in Diastolic Blood Pressure","timeFrame":"Baseline, 56 weeks"},{"measure":"Change in IDS-SR Total Scores","description":"IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression.","timeFrame":"Baseline, 56 weeks"},{"measure":"Change in Food Craving Inventory Sweets Subscale Score","description":"The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).","timeFrame":"Baseline, 56 weeks"},{"measure":"Change in Food Craving Inventory Carbohydrates Subscale Score","description":"The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).","timeFrame":"Baseline, 56 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female or male subjects aged 18 to 70 years of age (inclusive)\n* Body mass index (BMI) ≥27 and ≤45 kg/m²\n* Diagnosed with type 2 diabetes mellitus and on no injectable antidiabetes medication or inhaled insulin for more than 3 months prior to randomization\n* Took stable doses of oral single or combination hypoglycemic medications (biguanides, thiazolidinediones, meglitinides, α-glucosidase inhibitors, sulfonylureas, DPP4 inhibitors) for at least 3 months prior to randomization or did not take medications for the treatment of type 2 diabetes mellitus\n* Normotensive (systolic ≤145 mm Hg and diastolic ≤95 mm Hg). Antihypertensive medications were allowed with the exception of alpha-adrenergic blockers, and clonidine. Antihypertensive treatment was stable for at least 4 weeks prior to randomization.\n* Medications for the treatment of dyslipidemia were allowed with the exception of cholestyramine and cholestypol as long as the medical regimen had been stable for at least 4 weeks prior to randomization.\n* Free of opioid medication for 7 days prior to randomization\n* HbA1c between 7% and 10%, fasting blood glucose \\<270 mg/dL, and fasting triglycerides \\<400 mg/dL\n* No clinically significant abnormality of serum albumin, blood urea nitrogen (BUN), bilirubin, calcium, and phosphorus\n* Creatinine levels were ≤1.4 mg/dL for female subjects and ≤1.5 mg/dL for male subjects\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were within 2.5 × upper limit of laboratory normal range (ULN)\n* No clinically significant abnormality of hematocrit, white blood cell (WBC) count, WBC differential, or platelets\n* No clinically significant abnormality on urinalysis\n* TSH within normal limits or normal T3, if TSH is below normal limits\n* Female subjects of childbearing potential had a negative serum pregnancy test\n* Negative urine drug screen\n* An IDS-SR score \\<2 on individual items 5 (sadness), 6 (irritability), 7 (anxiety/tension), and 18 (suicidality) and an IDS-SR total score \\<30\n* Female subjects of childbearing potential were non-lactating and agreed to continue to use effective contraception throughout the study and 30 days after discontinuation of study drug\n* Able to comply with all required study procedures and schedule\n* Able to speak and read English\n* Provided written informed consent\n\nExclusion Criteria:\n\n* Type I diabetes mellitus\n* \"Brittle-diabetes\" or any hospitalization or emergency room visit due to poor diabetic control within 6 months prior to screening, history of diabetes-related dehydration leading to hospitalization, or history or evidence of ketoacidosis\n* Obesity of known endocrine origin other than diabetes mellitus (e.g., untreated hypothyroidism, Cushing's syndrome, established polycystic ovary syndrome)\n* Diabetes mellitus secondary to pancreatitis or pancreatectomy\n* Serious medical condition including but not limited to renal or hepatic insufficiency and Class III or IV congestive heart failure; history of myocardial infarction, angina pectoris, claudication, or acute limb ischemia within 6 months prior to screening; lifetime history of stroke\n* History of malignancy with exception of non-melanoma skin cancer or surgically cured cervical cancer within 5 years prior to screening\n* Loss or gain of more than 5.0 kg within the 3 months prior to screening\n* Severe microvascular or macrovascular complications of diabetes, including but not limited to proliferative retinopathy, active limb ulcerations, amputation of metatarsals or above\n* Serious psychiatric illness, including lifetime history of bipolar disorder, schizophrenia or other psychosis, bulimia, and anorexia nervosa; current serious personality disorder (e.g., borderline or antisocial); current severe major depressive disorder; recent (6 months prior to screening) suicide attempt or current active suicidal ideation; or recent hospitalization due to psychiatric illness\n* Response to the bipolar disorder questions that indicated the presence of bipolar disorder\n* Required medications for the treatment of a psychiatric disorder (with the exception of short term insomnia) within 6 months prior to screening\n* History of drug or alcohol abuse or dependence within 1 year prior to screening\n* Baseline ECG with a QTc interval (Bazett's formula) \\>450 msec (men) and \\>470 msec (women) or the presence of any clinically significant cardiac abnormalities, including but not limited to patterns consistent with recent myocardial ischemia, electrolyte abnormalities, or atrial or ventricular dysrhythmia or significant conduction abnormalities\n* Received the following excluded concomitant medications: any psychotropic agents (including antipsychotic, antidepressant, anxiolytic, mood stabilizer, anticonvulsant agents, and agents for the treatment of attention deficit disorder) with the exception of low-dose benzodiazepine or hypnotic agents for the treatment of insomnia (up to 2 mg lorazepam/day or equivalent dose of a benzodiazepine or hypnotic agent); any anorectic or weight loss agents; any over-the-counter dietary supplements or herbs with psychoactive, appetite, or weight effects; alpha-adrenergic blockers; dopamine agonists; clonidine; coumadin; theophylline; cimetidine; oral corticosteroids; cholestyramine, cholestypol, Depo Provera®; smoking cessation agents; use of opioid or opioid-like medications, including analgesics and antitussives\n* History of surgical or device intervention for obesity (e.g., gastric banding)\n* History of seizures of any etiology, or of predisposition to seizures (e.g., history of cerebrovascular accident, head trauma with ≥5 minutes loss of consciousness, concussion symptoms lasting ≥15 minutes, brain surgery, skull fracture, subdural hematoma, or febrile seizures)\n* Treatment with bupropion or naltrexone within 12 months prior to screening\n* History of hypersensitivity or intolerance to bupropion or naltrexone\n* Changes in smoking status or in tobacco or nicotine use within 3 months prior to screening or planned during study participation\n* Participated in a weight loss management program within one month prior to randomization\n* Females who were pregnant or breast-feeding or planned to become pregnant during the study period or within 30 days of discontinuing study drug\n* Planned surgical procedure that could impact the conduct of the study\n* Received any investigational drug or used an experimental device or procedure within the previous 30 days\n* Participated in any previous clinical trial conducted by Orexigen\n* Had any condition that in the opinion of the investigator made the subject unsuitable for inclusion into the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"SelfCenter, PC","city":"Fairhope","state":"Alabama","zip":"36532","country":"United States","geoPoint":{"lat":30.52297,"lon":-87.90333}},{"facility":"Pivotal Research Centers","city":"Peoria","state":"Arizona","zip":"85381","country":"United States","geoPoint":{"lat":33.5806,"lon":-112.23738}},{"facility":"HOPE Research Institute","city":"Phoenix","state":"Arizona","zip":"85050","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"HealthStar Research","city":"Hot Springs","state":"Arkansas","zip":"71913","country":"United States","geoPoint":{"lat":34.5037,"lon":-93.05518}},{"facility":"Impact Clinical Trials","city":"Beverly Hills","state":"California","zip":"90211","country":"United States","geoPoint":{"lat":34.07362,"lon":-118.40036}},{"facility":"Northern California Research","city":"Carmichael","state":"California","zip":"98608","country":"United States","geoPoint":{"lat":38.61713,"lon":-121.32828}},{"facility":"Sierra Medical Research","city":"Fresno","state":"California","zip":"93710","country":"United States","geoPoint":{"lat":36.74773,"lon":-119.77237}},{"facility":"Advance Clinical Research Institute","city":"Orange","state":"California","zip":"92869","country":"United States","geoPoint":{"lat":33.78779,"lon":-117.85311}},{"facility":"Affiliated Research Institute","city":"San Diego","state":"California","zip":"92108","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"VA San Diego Healthcare System","city":"San Diego","state":"California","zip":"92161","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Apex Research Institue","city":"Santa Ana","state":"California","zip":"92705","country":"United States","geoPoint":{"lat":33.74557,"lon":-117.86783}},{"facility":"Chase Medical Research, LLC","city":"Waterbury","state":"Connecticut","zip":"06708","country":"United States","geoPoint":{"lat":41.55815,"lon":-73.0515}},{"facility":"LCFP Inc.","city":"Fort Myers","state":"Florida","zip":"33907","country":"United States","geoPoint":{"lat":26.62168,"lon":-81.84059}},{"facility":"Miami Research Associates","city":"Miami","state":"Florida","zip":"33143","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Suncoast Clinical Research","city":"Palm Harbor","state":"Florida","zip":"34684","country":"United States","geoPoint":{"lat":28.07807,"lon":-82.76371}},{"facility":"University Clinical Research","city":"Pembroke Pines","state":"Florida","zip":"33024","country":"United States","geoPoint":{"lat":26.00315,"lon":-80.22394}},{"facility":"CSRA Partners in Health, Inc","city":"Augusta","state":"Georgia","zip":"30909","country":"United States","geoPoint":{"lat":33.47097,"lon":-81.97484}},{"facility":"East-West Medical Research Institute","city":"Honolulu","state":"Hawaii","zip":"96814","country":"United States","geoPoint":{"lat":21.30694,"lon":-157.85833}},{"facility":"Deaconess Clinic","city":"Evansville","state":"Indiana","zip":"47713","country":"United States","geoPoint":{"lat":37.97476,"lon":-87.55585}},{"facility":"Northwest Indiana Center for Clinical Research","city":"Valparaiso","state":"Indiana","zip":"46383","country":"United States","geoPoint":{"lat":41.47309,"lon":-87.06114}},{"facility":"Central Kentucky Research Associates, Inc.","city":"Lexington","state":"Kentucky","zip":"40509","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"L-Marc","city":"Louisville","state":"Kentucky","zip":"40213","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"Trover Center for Clinical Studies","city":"Madisonville","state":"Kentucky","zip":"42431","country":"United States","geoPoint":{"lat":37.3281,"lon":-87.49889}},{"facility":"Pennington Biomedical Research Center","city":"Baton Rouge","state":"Louisiana","zip":"70808","country":"United States","geoPoint":{"lat":30.44332,"lon":-91.18747}},{"facility":"Medical Research Institute","city":"Slidell","state":"Louisiana","zip":"70458","country":"United States","geoPoint":{"lat":30.27519,"lon":-89.78117}},{"facility":"Health Trends Research, LLC","city":"Baltimore","state":"Maryland","zip":"21209","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"FutureCare Studies","city":"Springfield","state":"Massachusetts","zip":"01103","country":"United States","geoPoint":{"lat":42.10148,"lon":-72.58981}},{"facility":"Twin Cities Clinical Research","city":"Brooklyn Center","state":"Minnesota","zip":"55430","country":"United States","geoPoint":{"lat":45.07608,"lon":-93.33273}},{"facility":"The Center for Pharmaceutical Research","city":"Kansas City","state":"Missouri","zip":"64114","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"Mercy Health Research","city":"St Louis","state":"Missouri","zip":"63141","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Radiant Research, Inc.","city":"St Louis","state":"Missouri","zip":"63141","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Center for Nutrition and Metabolic Diseases, Univ. of Nevada","city":"Reno","state":"Nevada","zip":"89557","country":"United States","geoPoint":{"lat":39.52963,"lon":-119.8138}},{"facility":"Endocrinology & Diabetes Consultants","city":"Dover","state":"New Hampshire","zip":"03820","country":"United States","geoPoint":{"lat":43.19786,"lon":-70.87367}},{"facility":"Lovelace Scientific Resources","city":"Albuquerque","state":"New Mexico","zip":"87108","country":"United States","geoPoint":{"lat":35.08449,"lon":-106.65114}},{"facility":"Diabetes care and Information Center","city":"Flushing","state":"New York","zip":"11365","country":"United States","geoPoint":{"lat":40.76538,"lon":-73.81736}},{"facility":"Central New York Clinical Research","city":"Manlius","state":"New York","zip":"13104","country":"United States","geoPoint":{"lat":43.00201,"lon":-75.97686}},{"facility":"Rochester Clinical Research, Inc","city":"Rochester","state":"New York","zip":"14609","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"Metrolina Medical Research","city":"Charlotte","state":"North Carolina","zip":"28209","country":"United States","geoPoint":{"lat":35.22709,"lon":-80.84313}},{"facility":"Rapid Medical Research, Inc.","city":"Cleveland","state":"Ohio","zip":"44122","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Central Ohio Nutrition Center, Inc.","city":"Columbus","state":"Ohio","zip":"43213","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Wells Institute for Health Awareness","city":"Kettering","state":"Ohio","zip":"45429","country":"United States","geoPoint":{"lat":39.6895,"lon":-84.16883}},{"facility":"Your Diabetes Endocrine and Nutrition Group","city":"Mentor","state":"Ohio","zip":"44060","country":"United States","geoPoint":{"lat":41.66616,"lon":-81.33955}},{"facility":"Mountain View Clinical Research","city":"Greer","state":"South Carolina","zip":"29349","country":"United States","geoPoint":{"lat":34.93873,"lon":-82.22706}},{"facility":"Palmetto Medical Research","city":"Mt. Pleasant","state":"South Carolina","zip":"29464","country":"United States","geoPoint":{"lat":32.79407,"lon":-79.86259}},{"facility":"ClinSearch","city":"Chattanooga","state":"Tennessee","zip":"37404","country":"United States","geoPoint":{"lat":35.04563,"lon":-85.30968}},{"facility":"Clinical Research Associates, Inc.","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"The Cooper Institute","city":"Dallas","state":"Texas","zip":"75230","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Baylor Endocrine Center","city":"Dallas","state":"Texas","zip":"75246","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Diabetes Center of the Southwest","city":"Midland","state":"Texas","zip":"79705","country":"United States","geoPoint":{"lat":31.99735,"lon":-102.07791}},{"facility":"InVisions Consultants, LLC","city":"San Antonio","state":"Texas","zip":"78217","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Diabetes & Glandular Disease Research Associates, Inc.","city":"San Antonio","state":"Texas","zip":"78229-4801","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Summit Research Network, Inc.","city":"Seattle","state":"Washington","zip":"98104","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Northside Internal Medicine","city":"Spokane","state":"Washington","zip":"99208","country":"United States","geoPoint":{"lat":47.65966,"lon":-117.42908}}]},"referencesModule":{"references":[{"pmid":"24144653","type":"RESULT","citation":"Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, Klassen P, Fujioka K; COR-Diabetes Study Group. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013 Dec;36(12):4022-9. doi: 10.2337/dc13-0234. Epub 2013 Oct 21."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg/day"},{"id":"FG001","title":"Placebo","description":"Placebo"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"335"},{"groupId":"FG001","numSubjects":"170"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"175"},{"groupId":"FG001","numSubjects":"100"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"160"},{"groupId":"FG001","numSubjects":"70"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"98"},{"groupId":"FG001","numSubjects":"26"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"15"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"21"},{"groupId":"FG001","numSubjects":"15"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Drug noncompliance, other","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"4"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All randomized subjects","groups":[{"id":"BG000","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg/day"},{"id":"BG001","title":"Placebo","description":"Placebo"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"335"},{"groupId":"BG001","value":"170"},{"groupId":"BG002","value":"505"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"54.02","spread":"9.05"},{"groupId":"BG001","value":"53.46","spread":"9.83"},{"groupId":"BG002","value":"53.83","spread":"9.32"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"195"},{"groupId":"BG001","value":"90"},{"groupId":"BG002","value":"285"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"140"},{"groupId":"BG001","value":"80"},{"groupId":"BG002","value":"220"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"261"},{"groupId":"BG001","value":"140"},{"groupId":"BG002","value":"401"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"81"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"12"}]}]},{"title":"Native Hawaiian or Other Pacific Islander","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]},{"title":"American Indian or Alaska Native","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"6"}]}]}]},{"title":"Weight","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"104.22","spread":"18.93"},{"groupId":"BG001","value":"105.08","spread":"16.99"},{"groupId":"BG002","value":"104.51","spread":"18.28"}]}]}]},{"title":"BMI","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg/m^2","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"36.40","spread":"4.75"},{"groupId":"BG001","value":"36.40","spread":"4.50"},{"groupId":"BG002","value":"36.40","spread":"4.66"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Co-primary: Body Weight- Mean Percent Change","populationDescription":"Modified ITT (Full Analysis Set): Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"percentage of body weight","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg/day"},{"id":"OG001","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"159"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.03","spread":"0.34"},{"groupId":"OG001","value":"-1.75","spread":"0.43"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-3.28","ciPctValue":"95","ciLowerLimit":"-4.34","ciUpperLimit":"-2.22"}]},{"type":"SECONDARY","title":"Change in HbA1c Levels","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"percent","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB32","description":"Naltrexone SR 32 mg/bupropion SR 360 mg/ day"},{"id":"OG001","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"137"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.63","spread":"0.07"},{"groupId":"OG001","value":"-0.14","spread":"0.09"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-0.49","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.71","ciUpperLimit":"-0.27"}]},{"type":"PRIMARY","title":"Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg/day"},{"id":"OG001","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"159"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.53","lowerLimit":"38.54","upperLimit":"50.51"},{"groupId":"OG001","value":"18.87","lowerLimit":"12.79","upperLimit":"24.95"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"3.44","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.15","ciUpperLimit":"5.50"}]},{"type":"SECONDARY","title":"Change in Fasting Triglycerides Levels, Using Log-transformed Data","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"percent change","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg/day"},{"id":"OG001","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"135"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.20","lowerLimit":"-15.59","upperLimit":"-6.58"},{"groupId":"OG001","value":"-0.80","lowerLimit":"-6.95","upperLimit":"5.76"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.007","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-10.4","ciNumSides":"TWO_SIDED"}]},{"type":"SECONDARY","title":"Change in Fasting HDL Cholesterol Levels","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mg/dL","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg/day"},{"id":"OG001","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"135"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.03","spread":"0.49"},{"groupId":"OG001","value":"-0.29","spread":"0.61"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"3.32","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.80","ciUpperLimit":"4.84"}]},{"type":"SECONDARY","title":"Change in Fasting Blood Glucose Levels","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mg/dL","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg/day"},{"id":"OG001","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"264"},{"groupId":"OG001","value":"158"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.87","spread":"2.70"},{"groupId":"OG001","value":"-4.02","spread":"3.39"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.065","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-7.85","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-16.21","ciUpperLimit":"0.50"}]},{"type":"SECONDARY","title":"Change in Waist Circumference","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"cm","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg/day"},{"id":"OG001","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"208"},{"groupId":"OG001","value":"124"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.97","spread":"0.47"},{"groupId":"OG001","value":"-2.89","spread":"0.61"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Mean Difference (Net)","paramValue":"-2.08","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.57","ciUpperLimit":"-0.59"}]},{"type":"SECONDARY","title":"Body Weight- Proportion of Subjects With ≥10% Decrease","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg/day"},{"id":"OG001","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"159"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.49","lowerLimit":"13.82","upperLimit":"23.16"},{"groupId":"OG001","value":"5.66","lowerLimit":"2.07","upperLimit":"9.25"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Odds Ratio (OR)","paramValue":"3.75","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.79","ciUpperLimit":"7.88"}]},{"type":"SECONDARY","title":"HbA1c- Proportion of Subjects With HbA1c <7% at Endpoint","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg/day"},{"id":"OG001","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"137"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.14","lowerLimit":"37.61","upperLimit":"50.68"},{"groupId":"OG001","value":"26.28","lowerLimit":"18.91","upperLimit":"33.65"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Odds Ratio (OR)","paramValue":"2.46","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.50","ciUpperLimit":"4.04"}]},{"type":"SECONDARY","title":"Percent of Subjects Requiring Rescue Medications for Diabetes","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg/day"},{"id":"OG001","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"159"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.26","lowerLimit":"19.05","upperLimit":"29.91"},{"groupId":"OG001","value":"35.22","lowerLimit":"29.81","upperLimit":"45.36"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Odds Ratio (OR)","paramValue":"0.55","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.35","ciUpperLimit":"0.86"}]},{"type":"SECONDARY","title":"Percent of Subjects With Dose Reduction in Oral Antidiabetes Medications","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg/day"},{"id":"OG001","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"159"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.89","lowerLimit":"0.28","upperLimit":"3.87"},{"groupId":"OG001","value":"1.26","lowerLimit":"0.00","upperLimit":"3.19"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Odds Ratio (OR)","paramValue":"1.43","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.27","ciUpperLimit":"7.57"}]},{"type":"SECONDARY","title":"Percent of Subjects With Dose Increase in Oral Antidiabetes Medications","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg/day"},{"id":"OG001","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"159"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.02","lowerLimit":"1.06","upperLimit":"5.58"},{"groupId":"OG001","value":"1.26","lowerLimit":"0.00","upperLimit":"3.19"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Odds Ratio (OR)","paramValue":"2.63","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.55","ciUpperLimit":"12.67"}]},{"type":"SECONDARY","title":"Change in HOMA-IR Levels, Using Log-transformed Data","description":"HOMA-IR= Homeostasis Model Assessment-Insulin Resistance","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"percent change","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg/day"},{"id":"OG001","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"112"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.56","lowerLimit":"-27.77","upperLimit":"-12.62"},{"groupId":"OG001","value":"-14.67","lowerLimit":"-24.69","upperLimit":"-3.31"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Mean Difference (Net)","paramValue":"-5.89","ciNumSides":"TWO_SIDED"}]},{"type":"SECONDARY","title":"Change in Fasting Insulin Levels, Using Log-transformed Data","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"percent change","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg/day"},{"id":"OG001","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"201"},{"groupId":"OG001","value":"113"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.48","lowerLimit":"-19.70","upperLimit":"-6.78"},{"groupId":"OG001","value":"-10.35","lowerLimit":"-18.75","upperLimit":"-1.09"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Mean Difference (Net)","paramValue":"-3.13","ciNumSides":"TWO_SIDED"}]},{"type":"SECONDARY","title":"HbA1c- Proportion of Subjects With HbA1c <6.5% at Endpoint","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg/day"},{"id":"OG001","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"137"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.72","lowerLimit":"15.39","upperLimit":"26.05"},{"groupId":"OG001","value":"10.22","lowerLimit":"5.15","upperLimit":"15.29"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Odds Ratio (OR)","paramValue":"2.64","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.36","ciUpperLimit":"5.14"}]},{"type":"SECONDARY","title":"Change in IWQOL-Lite Total Scores","description":"IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg/day"},{"id":"OG001","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"153"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.27","spread":"0.70"},{"groupId":"OG001","value":"7.90","spread":"0.86"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Mean Difference (Net)","paramValue":"1.37","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.77","ciUpperLimit":"3.51"}]},{"type":"SECONDARY","title":"Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"percent change","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg/day"},{"id":"OG001","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"202"},{"groupId":"OG001","value":"119"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.91","lowerLimit":"-29.29","upperLimit":"-11.54"},{"groupId":"OG001","value":"-13.29","lowerLimit":"-24.94","upperLimit":"0.17"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Mean Difference (Net)","paramValue":"-7.62","ciNumSides":"TWO_SIDED"}]},{"type":"SECONDARY","title":"Percent of Subjects Discontinuing Due to Poor Glycemic Control","description":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed. Odds ratio not calculated as there were no subjects in the NB32 group that discontinued due to poor glycemic control.","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg/day"},{"id":"OG001","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"159"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"NA","upperLimit":"NA","comment":"There were no subjects in the NB32 group that discontinued due to poor glycemic control."},{"groupId":"OG001","value":"1.89","lowerLimit":"0.00","upperLimit":"4.00"}]}]}]},{"type":"SECONDARY","title":"Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire","description":"Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg/day"},{"id":"OG001","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"146"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.89","spread":"1.39"},{"groupId":"OG001","value":"-6.91","spread":"1.69"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Mean Difference (Net)","paramValue":"-4.98","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-9.22","ciUpperLimit":"-0.74"}]},{"type":"SECONDARY","title":"Change in Fasting LDL Cholesterol Levels","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mg/dL","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg/day"},{"id":"OG001","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"220"},{"groupId":"OG001","value":"134"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.44","spread":"1.94"},{"groupId":"OG001","value":"-0.01","spread":"2.44"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Mean Difference (Net)","paramValue":"-1.43","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-7.48","ciUpperLimit":"4.62"}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mm Hg","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg/day"},{"id":"OG001","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"159"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.70"},{"groupId":"OG001","value":"-1.12","spread":"0.88"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Mean Difference (Net)","paramValue":"1.16","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.02","ciUpperLimit":"3.33"}]},{"type":"SECONDARY","title":"Change in Diastolic Blood Pressure","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mm Hg","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg/day"},{"id":"OG001","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"159"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.06","spread":"0.47"},{"groupId":"OG001","value":"-1.47","spread":"0.59"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Mean Difference (Net)","paramValue":"0.41","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.04","ciUpperLimit":"1.86"}]},{"type":"SECONDARY","title":"Change in IDS-SR Total Scores","description":"IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression.","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg/day"},{"id":"OG001","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"159"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.33"},{"groupId":"OG001","value":"-1.60","spread":"0.42"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Mean Difference (Net)","paramValue":"1.62","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.59","ciUpperLimit":"2.65"}]},{"type":"SECONDARY","title":"Change in Food Craving Inventory Sweets Subscale Score","description":"The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg/day"},{"id":"OG001","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"155"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.97","spread":"0.28"},{"groupId":"OG001","value":"-2.40","spread":"0.34"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Mean Difference (Net)","paramValue":"0.43","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.42","ciUpperLimit":"1.27"}]},{"type":"SECONDARY","title":"Change in Food Craving Inventory Carbohydrates Subscale Score","description":"The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).","populationDescription":"Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 56 weeks","groups":[{"id":"OG000","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg/day"},{"id":"OG001","title":"Placebo","description":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"155"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.48","spread":"0.26"},{"groupId":"OG001","value":"-1.52","spread":"0.32"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValueComment":"Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.","paramType":"Mean Difference (Net)","paramValue":"0.04","ciPctValue":"96","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.76","ciUpperLimit":"0.85"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Baseline, 56 weeks","description":"The safety analysis set includes all randomized subjects who took study drug and were assessed by investigator after their first dose, whether or not they discontinue the study. Treatment-emergent adverse events were defined as events that started or worsened in the double-blind treatment phase after the first dose and before 7 days post last dose.","eventGroups":[{"id":"EG000","title":"NB32","description":"Naltrexone SR 32 mg/Bupropion SR 360 mg daily","seriousNumAffected":13,"seriousNumAtRisk":333,"otherNumAffected":275,"otherNumAtRisk":333},{"id":"EG001","title":"Placebo","description":"Placebo","seriousNumAffected":8,"seriousNumAtRisk":169,"otherNumAffected":109,"otherNumAtRisk":169}],"seriousEvents":[{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":333},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":169}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":333},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":169}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":333},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":169}]},{"term":"Coronary artery occlusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":333},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":169}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":333},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":169}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":333},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":169}]},{"term":"Inguinal hernia, obstructive","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":333},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":169}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":333},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":169}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":333},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":169}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":333},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":169}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":333},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":169}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":333},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":169}]},{"term":"Lobar pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":333},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":169}]},{"term":"Staphylococcal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":333},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":169}]},{"term":"Troponin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":333},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":169}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":333},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":169}]},{"term":"Breast cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":333},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":169}]},{"term":"Colon cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":333},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":169}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":333},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":169}]},{"term":"Grand mal convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":333},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":169}]},{"term":"Syncope vasovagal","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":333},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":169}]},{"term":"Calculus ureteric","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":333},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":169}]}],"otherEvents":[{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":18,"numAffected":17,"numAtRisk":333},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":169}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":69,"numAffected":59,"numAtRisk":333},{"groupId":"EG001","numEvents":13,"numAffected":12,"numAtRisk":169}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":60,"numAffected":52,"numAtRisk":333},{"groupId":"EG001","numEvents":21,"numAffected":16,"numAtRisk":169}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":22,"numAffected":21,"numAtRisk":333},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":169}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":196,"numAffected":141,"numAtRisk":333},{"groupId":"EG001","numEvents":13,"numAffected":12,"numAtRisk":169}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":80,"numAffected":61,"numAtRisk":333},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":169}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":333},{"groupId":"EG001","numEvents":15,"numAffected":10,"numAtRisk":169}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":333},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":169}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":32,"numAffected":28,"numAtRisk":333},{"groupId":"EG001","numEvents":25,"numAffected":23,"numAtRisk":169}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":19,"numAffected":16,"numAtRisk":333},{"groupId":"EG001","numEvents":19,"numAffected":14,"numAtRisk":169}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":30,"numAffected":26,"numAtRisk":333},{"groupId":"EG001","numEvents":22,"numAffected":16,"numAtRisk":169}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":16,"numAffected":15,"numAtRisk":333},{"groupId":"EG001","numEvents":15,"numAffected":15,"numAtRisk":169}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":65,"numAffected":25,"numAtRisk":333},{"groupId":"EG001","numEvents":18,"numAffected":12,"numAtRisk":169}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":11,"numAffected":9,"numAtRisk":333},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":169}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":15,"numAffected":13,"numAtRisk":333},{"groupId":"EG001","numEvents":13,"numAffected":12,"numAtRisk":169}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":52,"numAffected":39,"numAtRisk":333},{"groupId":"EG001","numEvents":11,"numAffected":9,"numAtRisk":169}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":53,"numAffected":46,"numAtRisk":333},{"groupId":"EG001","numEvents":18,"numAffected":15,"numAtRisk":169}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":26,"numAffected":22,"numAtRisk":333},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":169}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":20,"numAffected":18,"numAtRisk":333},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":169}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":42,"numAffected":37,"numAtRisk":333},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":169}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 9.1","stats":[{"groupId":"EG000","numEvents":33,"numAffected":33,"numAtRisk":333},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":169}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"If not already published by Sponsor as part of a multi-center publication, 18 months after conclusion of the study at all study centers, PI may publish the results for PI's study center individually. Prior to such publication, PI must provide Sponsor with at least 60 days to review and comment on the proposed publication. The review period may be extended by an additional 30 days upon request. Sponsor may delay publication for up to an additional 6 month period to file for patent protection."},"pointOfContact":{"title":"Senior Vice President, Head of Global Development","organization":"Orexigen Therapeutics, Inc.","email":"MedInfo@Orexigen.com","phone":"(858) 875-8600"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D009765","term":"Obesity"},{"id":"D050177","term":"Overweight"},{"id":"D003924","term":"Diabetes Mellitus, Type 2"}],"ancestors":[{"id":"D044343","term":"Overnutrition"},{"id":"D009748","term":"Nutrition Disorders"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D001835","term":"Body Weight"},{"id":"D012816","term":"Signs and Symptoms"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"},{"id":"D003920","term":"Diabetes Mellitus"},{"id":"D044882","term":"Glucose Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"}]}},"hasResults":true}